TYMS is also a target gene of three Breast cancer drugs (Fluorouracil, Gemcitabine and Capecitabine) and physically interacts with two genes from the Triple Negative pattern -NUF2 and NDC80 (Fig. 17). This evidence concerns the gene NUF2 and breast carcinoma.